| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT03975829 Pediatric Long-Term Follow-up and Rollover Study |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-29 | NCT02224781 Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and… |
Trial sites reduced: 843 -> 840 locations |
| 2026-05-29 | NCT02224781 Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and… |
date change Completion pushed: 2026-09-11 -> 2026-12-19 |
| 2026-05-20 | NCT04439292 Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF… |
Enrollment increased: 35 -> 44 participants |
| 2026-05-16 | NCT06475989 Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer |
Trial sites expanded: 112 -> 301 locations |
| 2026-05-15 | NCT01947023 Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot… |
date change Primary completion moved earlier: 2026-06-01 -> 2026-04-29 |
| 2026-05-15 | NCT01947023 Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot… |
date change Completion pushed: 2026-06-01 -> 2027-05-12 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | Melanoma | Recruiting |
| NCT03975829 | Pediatric Long-Term Follow-up and Rollover Study | Diffuse Astrocytoma | Active, Not Recruiting |
| Phase 3 | |||
| NCT06475989 | Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer | Refractory Differentiated Thyroid Gland Carcinoma | Recruiting |
| NCT02224781 | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and… | Clinical Stage III Cutaneous Melanoma AJCC v8 | Active, Not Recruiting |
| NCT04940052 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously… | Differentiated Thyroid Cancer (DTC) | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult… | Haematological Malignancy | Not Yet Recruiting |
| Phase 2 | |||
| NCT07506109 | A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in… | BRAF V600E | Recruiting |
| NCT04116541 | A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular… | Malignant Solid Tumor | Recruiting |
| NCT07110246 | Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas | BRAF V600 Mutation | Recruiting |
| NCT02231775 | Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C… | Stage IIIB Cutaneous Melanoma AJCC v7 | Active, Not Recruiting |
| NCT04675710 | Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of… | Thyroid Gland Anaplastic Carcinoma | Active, Not Recruiting |
| NCT03149029 | Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma | Metastatic Melanoma | Active, Not Recruiting |
| NCT03919071 | Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With… | Anaplastic Astrocytoma | Active, Not Recruiting |
| NCT02196181 | Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer… | Stage III Cutaneous Melanoma AJCC v7 | Active, Not Recruiting |
| NCT04439292 | Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF… | Advanced Lymphoma | Active, Not Recruiting |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced… | Advanced Lymphoma | Active, Not Recruiting |
| NCT02910700 | Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating… | Metastatic Malignant Neoplasm in the Brain | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT04201457 | A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG… | Low Grade Glioma (LGG) of Brain With BRAF Aberration | Active, Not Recruiting |
| NCT04557956 | Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment… | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Active, Not Recruiting |
| NCT01989585 | Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in… | Clinical Stage III Cutaneous Melanoma AJCC v8 | Active, Not Recruiting |
| Phase 1 | |||
| NCT04903119 | Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma | Metastatic Melanoma | Recruiting |
| NCT03975231 | Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic… | BRAF NP_004324.2:p.V600E | Recruiting |
| NCT03091257 | A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory… | Multiple Myeloma | Active, Not Recruiting |
| NCT01947023 | Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot… | Metastatic Thyroid Gland Carcinoma | Active, Not Recruiting |
| Not specified | |||
| NCT04666272 | Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant… | Melanoma | Active, Not Recruiting |